Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
July 31, 2026Intestinal ResearchOpen Access

Anti-tumor necrosis factor-α therapy and paradoxical autoimmunity in inflammatory bowel disease: a need for risk-aware monitoring

View Full Paper
Ask AI
Bookmark
Share

Authors

JKJi Eun Kim

Discussion

Loading...

Member takes

Overview

Randomized trial shows increased risk of autoimmunity in IBD patients receiving anti-TNF therapy, suggesting vigilant monitoring is needed.

Key Points

  • This research aims to explore the association between anti-TNFα therapy and the risk of paradoxical autoimmunity in patients with inflammatory bowel disease (IBD).
  • Utilized a nationwide cohort study to evaluate the incidence of psoriasiform diseases in IBD patients on anti-TNF therapy.
  • Analyzed the mechanisms linking TNF inhibitors with Th1 and Th17 inflammatory pathways.
  • Highlighted the challenges in establishing causality for new respiratory symptoms during anti-TNF therapy.
  • A significant incidence of psoriasiform lesions was observed in IBD patients on anti-TNF therapy.
  • Korean nationwide cohort data confirmed an increased risk for psoriasiform conditions after TNF antagonist exposure.
  • Anti-TNF therapy may redirect immune activity rather than solely suppress it, necessitating risk-aware monitoring.

Cite This Study

Ji Eun Kim (2026) studied this question.

synapsesocial.com/papers/6a6c46c0747664a1aa73bb3dhttps://doi.org/10.5217/ir.2026.00169
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P0921 Paradoxical dermatological manifestations under anti-tnf therapy in patients with Inflammatory Bowel Disease2026
  2. 2Association between anti-tumor necrosis factor alpha exposure and new-onset autoimmune diseases in inflammatory bowel disease: a nationwide case-control study in Korea2026
  3. 3Risk of Paradoxical Rheumatoid Arthritis in Inflammatory Bowel Disease Patients Exposed to Tumor Necrosis Factor Inhibitors: A Propensity-Matched Multicenter Study2024
  4. 4P0673 Higher serum IL-23 levels associated with development of dermatological complications of anti-TNF therapy in Crohn’s Disease2026
  5. 5P0332 Unmasking a Hidden Foe: Miliary Tuberculosis in a Young Crohn’s Patient during Anti-TNF Therapy2026